- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07946757
Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B
A Multicenter, Randomized, Open-Label Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B(CHB)
This is a multicenter, randomized, open-label, parallel-controlled phase Ib clinical trial, which aims to evaluate the safety and preliminary efficacy of ACT201 injection combined with standard-of-care therapy (PegIFNα, NAs) in treatment-naive participants with chronic hepatitis B. A total of 60 treatment-naive participants with chronic hepatitis B are planned to be enrolled and randomized Treatment Group 1, Treatment Group 2, Treatment Group 3 or Treatment Group 4 for treatment.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
- Name: Minghui Li, Ph.D
- Telefonnummer: 010-84322284
- E-Mail: Wuhm2000@sina.com
Studienorte
-
-
-
Beijing, China
- Beijing Ditan Hospital, Capital Medical University
-
Kontakt:
- Minghui Li
-
Xi'an, China
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Kontakt:
- Shuangsuo Dang
-
Xiamen, China
- The First Affiliated Hospital of Xiamen University
-
Kontakt:
- Xiulan Xue
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Voluntarily participate in this trial and sign the informed consent form;
- Aged 18 to 65 years (inclusive), male or female;
- Body mass index (BMI) between 18 and 32 kg/m² (inclusive);
- HBsAg-positive or HBV DNA-positive for at least 6 months, or previous liver biopsy showing chronic HBV infection, or HBsAg-positive and anti-HBc IgM-negative at screening;
- No prior treatment with nucleos(t)ide analogues or interferons for chronic hepatitis B within 6 months before screening;
- HBsAg, HBeAg, HBV DNA and liver function indicators meet the protocol requirements;
- Willing to use effective contraception and have no plan for pregnancy, sperm donation or oocyte donation.
Exclusion Criteria:
- Subjects with recent major trauma or major surgery, or those scheduled to undergo surgery;
- Presence of clinically significant uncontrolled abnormalities or other severe diseases other than chronic HBV infection;
- History of other liver diseases;
- History of liver cirrhosis;
- Imaging suggestive of a suspected malignant hepatic lesion;
- Past or current evidence of hepatic decompensation;
- History of extrahepatic diseases potentially associated with HBV immune status;
- Other diseases associated with vasculitis;
- Infections (other than HBV) requiring systemic antiviral or antibacterial therapy at screening;
- History of malignancy;
- Prior solid organ or bone marrow transplantation;
- Presence or history of severe psychiatric disorders;
- Severe retinopathy or other serious ophthalmic diseases;
- Prior or current use of prohibited medications;
- Concomitant hematological diseases;
- Abnormal laboratory findings;
- Abnormal QTcF interval;
- History of allergy;
- Lactating female subjects or those with a positive serum pregnancy test at screening;
- Participation in another clinical trial, or failure to complete the washout period specified in the protocol prior to this trial;
- Any other condition that, in the opinion of the investigator, renders the subject unsuitable for participation in this trial.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Gruppe 2
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Experimental: Gruppe 1
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Experimental: Gruppe 3
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
|
Experimental: Gruppe 4
|
Subcutaneous injection per assigned treatment group; Treatment duration and dosing sequence shall be in accordance with the study protocol Subcutaneous injection per assigned treatment group; Treatment duration shall follow the study protocol Once daily, orally, until the end of the trial |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Safety: number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results. Assessments include vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms (ECGs)
Zeitfenster: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
HBsAg, HBsAb and HBV DNA levels and changes from baseline
Zeitfenster: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
|
HBsAg seroclearance rate
Zeitfenster: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
|
HBsAg seroconversion rate
Zeitfenster: throughout the full study period,an average of 38 weeks
|
throughout the full study period,an average of 38 weeks
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Minghui Li, Ph.D, Beijing Ditan Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- ACT201-4-1-002
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .